New study shows promising results successful treating pancreatic cancer – 1 of the astir assertive and hard to treat forms of cancer.
A team of scientists from Northwestern University (USA) developed a cause elraglusibwhich successful a objective trial showed improved survival rates when used successful operation with standard chemotherapy.
Clinical trial results
Research published successful the diary Nature Medicineincluded 233 patients with metastatic pancreatic crab from Europe and North America.
Participants were divided into two groups:
- the archetypal received standard chemotherapy,
- the 2nd is simply a operation of chemotherapy and a caller drug.
The results showed that average beingness expectancy accrued to 10.1 months successful patients treated with elraglusib compared with 7.2 months successful the power group.
Besides, the hazard of decease decreased by astir 38%.
Survival rates
- 44% patients successful the elraglusib radical were live astatine 1 year (vs. 22%),
- 13% – aft two years (in the power radical – 0%).
Side effects
Side effects were mostly accordant with those observed with chemotherapy, but there was slightly higher frequency successful the radical with a caller drug.
Among them:
- fatigue,
- decrease successful leukocyte levels,
- temporary visual impairment.
Most broadside effects person been recognized manageable and reversible.
Cautious Optimism
Despite the encouraging results, the researchers stress that we are talking astir early stage researchand the findings necessitate confirmation successful larger objective trials.
However, the work is seen arsenic an important step forward successful the treatment of a illness that remains 1 of the astir challenging tasks successful modern oncology.
Greek (GR) · 
English (US) ·